Recombinant Escherichia coli O157:H7 Prolipoprotein diacylglyceryl transferase (lgt)

What is Lgt and what role does it play in E. coli O157:H7?

Lgt (Prolipoprotein diacylglyceryl transferase) catalyzes the first essential step in the biogenesis of Gram-negative bacterial lipoproteins. In E. coli O157:H7, Lgt transfers a diacylglyceryl moiety from phosphatidylglycerol to a conserved cysteine residue in preprolipoprotein substrates via formation of a thioether bond . This modification is crucial for bacterial growth, outer membrane integrity, and pathogenesis. The E. coli O157:H7 Lgt protein consists of 291 amino acids and contains multiple transmembrane domains that anchor it in the inner membrane where it performs its catalytic function .

How does Lgt function in the bacterial lipoprotein maturation pathway?

Lgt functions as the first enzyme in a three-step sequential process of lipoprotein maturation:

• Lgt transfers the diacylglyceryl group from phosphatidylglycerol to the sulfhydryl group of the conserved cysteine in the lipobox motif of preprolipoproteins

• Lipoprotein signal peptidase (LspA) subsequently cleaves the signal peptide

• Apolipoprotein N-acyltransferase (Lnt) adds a third fatty acid to the amino group of the modified cysteine

Following these modifications, mature lipoproteins are transported to the outer membrane by the Lol transport system (LolCDE) . The coordinated action of these enzymes ensures proper lipoprotein maturation and localization, which is essential for maintaining outer membrane integrity in Gram-negative bacteria .

Why is Lgt considered a promising target for antibacterial development?

Lgt represents a compelling antibacterial target for several reasons:

• Essential function: Lgt depletion is lethal to pathogenic E. coli strains, including uropathogenic clinical isolates

• Modest inhibition is effective: Even partial depletion (~25%) of Lgt is sufficient for bactericidal activity, suggesting that incomplete inhibition by therapeutic agents could be clinically effective

• Membrane destabilization: Lgt inhibition leads to outer membrane permeabilization, increasing bacterial sensitivity to serum killing and antibiotics

• Resistance profile: Unlike inhibitors of other steps in lipoprotein biosynthesis, resistance to Lgt inhibition cannot be achieved through deletion of the major outer membrane lipoprotein (lpp)

• Conservation: Lgt is highly conserved across Gram-negative bacteria, suggesting broad-spectrum potential

Research has demonstrated that Lgt depletion results in significant attenuation in a mouse E. coli bacteremic infection model, further supporting its potential as a therapeutic target .

Experimental Approaches

Lgt enzymatic activity can be measured through several biochemical approaches:

• Glycerol phosphate release assay: This method measures the release of glycerol phosphate, a by-product of the Lgt-catalyzed transfer of diacylglyceryl from phosphatidylglycerol to a peptide substrate. The assay employs:

  • A peptide substrate derived from the Pal lipoprotein (Pal-IAAC, where C is the conserved cysteine modified by Lgt)

  • Detection of glycerol-1-phosphate (G1P) and glycerol-3-phosphate (G3P) released during the reaction

  • A coupled luciferase reaction for sensitive quantification

• Control validations: Negative controls using mutant Pal peptide substrate with the conserved cysteine mutated to alanine (Pal-IAA) can confirm assay specificity

This assay system has been instrumental in identifying and characterizing Lgt inhibitors with IC50 values in the sub-micromolar range (0.18-0.93 μM) .

What methods can detect different forms of lipoproteins after Lgt inhibition?

Several analytical methods can detect and differentiate lipoprotein forms resulting from Lgt inhibition:

• SDS fractionation and Western blot analysis:

  • Separation of SDS-insoluble peptidoglycan-associated proteins (PAP) from SDS-soluble non-PAP

  • Detection of various Lpp forms using specific antibodies

  • Identification of distinct migration patterns for different Lpp forms:

    • Unmodified pro-Lpp (UPLP): Accumulates after Lgt depletion

    • Diacylglyceryl-modified pro-Lpp (DGPLP): Accumulates after LspA depletion

    • Triacylated mature Lpp: Found in normal conditions

    • PG-linked Lpp forms: Enriched in PAP fraction

• Lysozyme treatment:

  • Addition of lysozyme allows identification of peptidoglycan-linked Lpp forms

  • Enhances detection sensitivity for specific Lpp modifications

These methods have been used to confirm that specific depletion of Lgt leads to accumulation of unmodified pro-Lpp, consistent with blockade of the first step in lipoprotein processing .

How does partial inhibition of Lgt affect bacterial cell physiology?

Partial inhibition of Lgt has profound effects on bacterial physiology, even when complete growth inhibition is not achieved:

• Membrane permeability changes: E. coli cells expressing as high as ~90% of normal Lgt levels show significantly increased incorporation of SYTOX Green, a dye that normally does not penetrate an intact outer membrane

• Serum sensitivity: Modest depletion of Lgt leads to increased sensitivity to complement-mediated killing, even in typically serum-resistant strains like E. coli CFT073

• Antibiotic susceptibility: Partial Lgt depletion that still allows normal growth in vitro results in increased sensitivity to antibiotics normally excluded by the impermeable Gram-negative outer membrane

• Morphological changes:

  • Increased cell size

  • Inner membrane contraction due to osmotic stress (Lpp-dependent)

  • Altered cellular ultrastructure

These findings suggest that even sub-lethal inhibition of Lgt could potentiate conventional antibiotics or host defense mechanisms, potentially offering advantages for therapeutic applications .

Why doesn't lpp deletion rescue growth after Lgt depletion, unlike with other lipoprotein biosynthesis inhibitors?

A key distinction between Lgt inhibition and inhibition of downstream lipoprotein processing enzymes lies in the lpp-independence of Lgt's essential function:

• Downstream inhibitors: Inhibition of LspA (the second enzyme in lipoprotein processing) or disruption of the Lol transport system can be rescued by deletion of lpp, suggesting that accumulation of toxic Lpp intermediates is the primary cause of lethality

• Lgt inhibition: Deletion of lpp is not sufficient to rescue growth after Lgt depletion or provide resistance to Lgt inhibitors

• Mechanistic implications: This suggests that Lgt's essential function extends beyond processing Lpp and likely involves multiple essential lipoproteins. The lethality associated with Lgt inhibition appears to result from global disruption of lipoprotein processing rather than toxic accumulation of a single intermediate

This mechanistic distinction has significant implications for antimicrobial development, as it suggests that Lgt inhibitors may be less susceptible to one of the most common resistance mechanisms that invalidate inhibitors of downstream steps in bacterial lipoprotein biosynthesis and transport .

What approaches have been used to identify and validate Lgt inhibitors?

The identification and validation of Lgt inhibitors has employed multiple complementary approaches:

• Initial discovery:

  • Screening for compounds that bind to purified Lgt protein

  • Biochemical assays measuring inhibition of enzymatic activity in vitro

• Validation of target engagement:

  • Comparison of phenotypes between inhibitor treatment and genetic depletion

  • Western blot detection of accumulated unmodified pro-Lpp after treatment

  • Measurement of outer membrane permeabilization using dye uptake assays

• Specificity confirmation:

  • Testing inhibitor activity in strains with reduced Lgt expression

  • Evaluating cross-species activity with Lgt proteins of varying sequence identity

  • Examining resistance mechanisms and attempting to generate resistant mutants

Notable Lgt inhibitors identified include compounds G9066, G2823, and G2824, which potently inhibit Lgt biochemical activity (IC50 values of 0.24 μM, 0.93 μM, and 0.18 μM, respectively) and demonstrate bactericidal activity against wild-type E. coli and A. baumannii strains .

What are the structural and functional characteristics of E. coli O157:H7 Lgt protein?

The E. coli O157:H7 Lgt protein possesses several key structural and functional characteristics:

• Protein structure:

  • 291 amino acid polypeptide

  • Multiple transmembrane domains creating a hydrophobic binding pocket

  • Conserved catalytic residues critical for enzymatic function

• Conservation: Significant sequence conservation exists among Lgt proteins from various bacterial species, with E. coli Lgt sharing 51.6% sequence identity with P. aeruginosa PA14 Lgt and 48.6% with A. baumannii ATCC 17978 Lgt

• Substrate specificity: Recognizes and modifies preprolipoproteins containing a conserved "lipobox" motif with a cysteine residue that becomes the N-terminal residue of the mature lipoprotein

This detailed structural and functional information provides a foundation for structure-based inhibitor design and rational modification of existing inhibitors .

How can one generate and validate conditional Lgt mutants in E. coli?

Generation of conditional Lgt mutants requires careful genetic manipulation due to Lgt's essential nature:

• Construction of arabinose-inducible system:

  • Replace the native lgt promoter with the arabinose-inducible araBAD promoter

  • Retain the lgt stop codon, which forms part of the thyA ribosomal binding site

  • Confirm that thyA expression remains unchanged to prevent polar effects

• Validation steps:

  • Verify arabinose-dependent growth

  • Demonstrate complementation with plasmid-encoded lgt

  • Confirm depletion of Lgt protein using western blot analysis

  • Verify accumulation of unprocessed lipoproteins upon Lgt depletion

• Critical considerations:

  • Monitor thyA expression levels, as thyA is downstream of lgt and its ribosome binding site overlaps with the lgt stop codon

  • Ensure tight control of the inducible promoter to prevent leaky expression

  • Account for the time required for existing Lgt depletion when removing the inducer

This approach has been successfully implemented in both laboratory and clinical isolates of E. coli, including the uropathogenic E. coli strain CFT073 .

What controls are essential when studying Lgt inhibition?

Robust experimental design for studying Lgt inhibition requires several critical controls:

• Genetic controls:

  • Inducible lgt deletion strains as positive controls for Lgt inhibition

  • Complemented strains expressing heterologous lgt genes to confirm specificity

  • Parallel studies with inducible deletion strains for other lipoprotein processing enzymes (lspA, lnt, lolCDE) to distinguish pathway-specific effects

• Biochemical assay controls:

  • Mutant peptide substrates (e.g., Pal-IAA with cysteine-to-alanine substitution)

  • Enzyme concentration controls and time-course experiments

  • Verification of substrate quality and reaction conditions

• Target engagement controls:

  • Western blot analysis to confirm accumulation of unmodified pro-Lpp

  • Comparison of phenotypes between inhibitor treatment and genetic depletion

  • Cross-resistance testing with other membrane-targeting agents

Implementation of these controls ensures reliable interpretation of results and clear differentiation between Lgt-specific effects and general membrane perturbations or off-target activities .

What phenotypic assays best demonstrate successful Lgt inhibition?

Several phenotypic assays effectively demonstrate successful Lgt inhibition:

• Membrane permeability assays:

  • SYTOX Green incorporation: Measures outer membrane permeabilization

  • Susceptibility to normally excluded antibiotics: Quantifies permeability changes

• Lipoprotein processing analysis:

  • Western blot detection of accumulated unmodified pro-Lpp

  • SDS fractionation to separate peptidoglycan-associated proteins

• Physiological consequences:

  • Microscopy for cell size and morphology changes

  • Serum sensitivity assays to assess complement resistance

  • In vivo infection models to evaluate attenuation

• Comparative metrics:

  • Quantitative comparison with genetic depletion phenotypes

  • Dose-dependent relationships between inhibition and phenotypic outcomes

The most convincing demonstration of Lgt inhibition combines biochemical evidence of target engagement with multiple phenotypic assays showing the expected spectrum of cellular consequences .

How can researchers differentiate between on-target and off-target effects of potential Lgt inhibitors?

Differentiating between on-target and off-target effects requires a multi-faceted approach:

• Biochemical confirmation:

  • Demonstration of direct Lgt enzyme inhibition in vitro

  • Structure-activity relationship studies correlating biochemical potency with cellular effects

• Genetic validation:

  • Testing in strains with reduced Lgt expression, which should show increased sensitivity to on-target inhibitors

  • Comparison of phenotypic profiles between inhibitor treatment and genetic Lgt depletion

• Specificity indicators:

  • Accumulation of the expected lipoprotein intermediate (unmodified pro-Lpp)

  • Lack of effect on other cellular processes at concentrations that inhibit Lgt

  • Conservation of activity across Lgt orthologs with significant sequence divergence

• Resistance studies:

  • Attempts to generate on-target resistant mutants (though the essential nature of Lgt may make this challenging)

  • Evaluation of potential resistance mechanisms

Research has shown that true Lgt inhibitors produce phenotypic signatures closely matching those observed with genetic Lgt depletion, including specific accumulation of unmodified pro-Lpp, outer membrane permeabilization, and increased antibiotic susceptibility .

What are the major challenges in developing potent and selective Lgt inhibitors?

Several challenges complicate the development of potent and selective Lgt inhibitors:

• Structural complexity: The membrane-embedded nature of Lgt creates difficulties for structural studies and rational inhibitor design

• Substrate binding sites: The current limited understanding of how inhibitors compete with either phosphatidylglycerol or prolipoprotein substrates hampers optimization efforts

• Resistance concerns: Although Lgt inhibitors may avoid common resistance mechanisms affecting other lipoprotein processing inhibitors, novel resistance mechanisms could potentially emerge

• Permeability barriers: The Gram-negative outer membrane presents permeability challenges for inhibitor entry, particularly for compounds targeting an inner membrane enzyme

• Selectivity issues: Ensuring selectivity against mammalian enzymes that process lipid-modified proteins presents another challenge for therapeutic development

Despite these challenges, the identification of the first Lgt inhibitors with sub-micromolar potency represents significant progress in this field .

How might Lgt inhibition be combined with other therapeutic approaches?

The unique mechanism of Lgt inhibition suggests several promising combinatorial approaches:

• Antibiotic potentiation:

  • Partial Lgt inhibition increases bacterial susceptibility to antibiotics normally excluded by the outer membrane

  • Combined therapy could reduce required antibiotic doses and expand the spectrum of effective antibiotics

• Immune potentiation:

  • Lgt inhibition increases bacterial sensitivity to serum killing

  • Combination with immune-stimulating agents could enhance clearance of Gram-negative infections

• Multi-target approaches:

  • Simultaneous inhibition of multiple steps in lipoprotein processing might create synergistic effects

  • Targeting both lipoprotein processing and other essential pathways could reduce resistance development

• Species-specific optimization:

  • Despite conservation, sequence differences in Lgt across bacterial species offer opportunities for pathogen-specific inhibitors

  • Tailored combinations could address specific infection scenarios

The observed bactericidal activity of Lgt inhibitors against wild-type strains of both E. coli and A. baumannii underscores the potential broad-spectrum applications of this approach .